An Operationally Seamless, Randomized Phase 2/3 Study Consisting of a Phase 2 Single-Blind, Dose-Evaluation Phase and a Phase 3 Double-Blind, Placebo-controlled Phase to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta
Description
A clinical trial examining the efficacy of Setrusumab in reducing fractures compared to a placebo for patients with Osteogenesis Imperfecta.
Details
Age
Child to Adult
Eligibility
Diagnosis of Osteogeneis Imperfecta Type 1,3, or 4
Type of Study
Treatment
Scope
National
Locations
Childrens Hospital Colorado
Principal Investigator
Klane White, MD, MSc
Study ID
Protocol Number: 22-2292
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers